New strategies in the management of leptomeningeal metastases

Archives of Neurology

Volumn 67, Issue 3, 2010, Pages 305-312

  Groves, Morris D ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 O BENZYLGUANINE; 7 ETHYL 10 HYDROXYCAMPTOTHECIN; ALPHA INTERFERON; ASPARAGINASE; AZACITIDINE; BUSULFAN; CARBOPLATIN; CISPLATIN; CLOFARABINE; CYTARABINE; DAUNORUBICIN; ERLOTINIB; ETOPOSIDE; FLOXURIDINE; FLUOROURACIL; GEMCITABINE; IDARUBICIN; MAFOSFAMIDE; MERCAPTOPURINE; METHOTREXATE; OXALIPLATIN; PEMETREXED; RITUXIMAB; SPIROMUSTINE; TEMOZOLOMIDE; THIOTEPA; TIAZOFURIN; TOPOTECAN; TRASTUZUMAB; UNINDEXED DRUG; VINCRISTINE SULFATE;

ARACHNOIDITIS; BACTERIAL MENINGITIS; BLOOD BRAIN BARRIER; BLOOD CEREBROSPINAL FLUID BARRIER; BONE MARROW SUPPRESSION; BRAIN METASTASIS; CANCER HORMONE THERAPY; CANCER IMMUNOTHERAPY; CONTINUOUS INFUSION; CRANIOTOMY; DRUG BLOOD LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; DRUG DELIVERY SYSTEM; DRUG INDUCED HEADACHE; DRUG MEGADOSE; EXPERIMENTAL THERAPY; GASTROINTESTINAL SYMPTOM; HUMAN; IRRITABILITY; LUNG NON SMALL CELL CANCER; MEDULLOBLASTOMA; MENINGEAL METASTASIS; MESOTHELIOMA; NECK PAIN; NONHUMAN; PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA; PRIORITY JOURNAL; REVIEW; SIDE EFFECT;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG DELIVERY SYSTEMS; HUMANS; MENINGEAL NEOPLASMS;

EID: 77949341062     PISSN: 00039942     EISSN: 15383687     Source Type: Journal    
DOI: 10.1001/archneurol.2010.18     Document Type: Review

References (119)

1. Posner JB. Neurologic Complications of Cancer. Philadelphia, PA: F. A. Davis Co; 1995.
2. Jaeckle KA. Neoplastic meningitis from systemic malignancies: diagnosis, prognosis and treatment. Semin Oncol. 2006;33(3):312-323.
3. Gleissner B, Chamberlain MC. Neoplastic meningitis. Lancet Neurol. 2006;5(5): 443-452.
4. Jaeckle KA, Phuphanich S, Bent MJ, et al. Intrathecal treatment of neoplastic meningitis due to breast cancer with a slow-release formulation of cytarabine. Br J Cancer. 2001;84(2):157-163.
5. Chamberlain MC, Kormanik P. Carcinoma meningitis secondary to non-small cell lung cancer: combined modality therapy. Arch Neurol. 1998;55(4):506-512.
6. Chamberlain MC, Kormanik PR. Carcinomatous meningitis secondary to breast cancer: predictors of response to combined modality therapy. J Neurooncol. 1997;35(1):55-64.
7. Nguyen DX, Bos PD, Massague J. Metastasis: from dissemination to organspecific colonization. Nat Rev Cancer. 2009;9(4):274-284.
8. Fidler IJ, Yano S, Zhang RD, Fujimaki T, Bucana CD. The seed and soil hypothesis: vascularisation and brain metastases. Lancet Oncol. 2002;3(1):53-57.
9. Groves MD. The pathogenesis of neoplastic meningitis. Curr Oncol Rep. 2003; 5(1):15-23.
10. Lorger M, Krueger JS, O'Neal M, Staflin K, Felding-Habermann B. Activation of tumor cell integrin {alpha}v{beta}3 controls angiogenesis and metastatic growth in the brain. Proc Natl Acad Sci U S A. 2009;106(26):10666-10671.
11. Lee TH, Avraham HK, Jiang S, Avraham S. Vascular endothelial growth factor modulates the transendothelial migration of MDA-MB-231 breast cancer cells through regulation of brain microvascular endothelial cell permeability. J Biol Chem. 2003;278(7):5277-5284.
12. Lee BC, Lee TH, Avraham S, Avraham HK. Involvement of the chemokine receptor CXCR4 and its ligand stromal cell-derived factor 1alpha in breast cancer cell migration through human brain microvascular endothelial cells. Mol Cancer Res. 2004;2(6):327-338.
13. Yang Y, Estrada EY, Thompson JF, Liu W, Rosenberg GA. Matrix metalloproteinase-mediated disruption of tight junction proteins in cerebral vessels is reversed by synthetic matrix metalloproteinase inhibitor in focal ischemia in rat. J Cereb Blood Flow Metab. 2007;27(4):697-709.
14. Shintani Y, Higashiyama S, Ohta M, et al. Overexpression of ADAM9 in nonsmall cell lung cancer correlates with brain metastasis. Cancer Res. 2004; 64(12):4190-4196.
15. Schackert G, Fidler IJ. Site-specific metastasis of mouse melanomas and a fibrosarcoma in the brain or meninges of syngeneic animals. Cancer Res. 1988; 48(12):3478-3484.
16. Palmieri D, Smith QR, Lockman PR, et al. Brain metastases of breast cancer. Breast Dis. 2006-2007;26:139-147.
17. Levin VA, Patlak CS, Landahl HD. Heuristic modeling of drug delivery to malignant brain tumors. J Pharmacokinet Biopharm. 1980;8(3):257-296.
18. Levin VA. Relationship of octanol/water partition coefficient and molecular weight to rat brain capillary permeability. J Med Chem. 1980;23(6):682-684.
19. Ghersi-Egea JF, Strazielle N. Brain drug delivery, drug metabolism, and multidrug resistance at the choroid plexus. Microsc Res Tech. 2001;52(1):83-88.
20. Taylor EM. The impact of efflux transporters in the brain on the development of drugs for CNS disorders. Clin Pharmacokinet. 2002;41(2):81-92.
21. Deguchi Y, Yokoyama Y, Sakamoto T, et al. Brain distribution of 6-mercaptopurine is regulated by the efflux transport system in the blood-brain barrier. Life Sci. 2000;66(7):649-662.
22. Potschka H, Fedrowitz M, Loscher W. Multidrug resistance protein MRP2 contributes to blood-brain barrier function and restricts antiepileptic drug activity. J Pharmacol Exp Ther. 2003;306(1):124-131.
23. Rao VV, Dahlheimer JL, Bardgett ME, et al. Choroid plexus epithelial expression of MDR1 P glycoprotein and multidrug resistance-associated protein contribute to the blood-cerebrospinal-fluid drug-permeability barrier. Proc Natl Acad Sci U S A. 1999;96(7):3900-3905.
24. Wijnholds J, deLange EC, Scheffer GL, et al. Multidrug resistance protein 1 protects the choroid plexus epithelium and contributes to the blood-cerebrospinal fluid barrier. J Clin Invest. 2000;105(3):279-285.
25. Deeken JF, Loscher W. The blood-brain barrier and cancer: transporters, treatment, and Trojan horses. Clin Cancer Res. 2007;13(6):1663-1674.
26. Strazielle N, Khuth ST, Ghersi-Egea JF. Detoxification systems, passive and specific transport for drugs at the blood-CSF barrier in normal and pathological situations. Adv Drug Deliv Rev. 2004;56(12):1717-1740.
27. Chen J, Balmaceda C, Bruce JN, et al. Tamoxifen paradoxically decreases paclitaxel deposition into cerebrospinal fluid of brain tumor patients. J Neurooncol. 2006;76(1):85-92.
28. Zhuang Y, Fraga CH, Hubbard KE, et al. Topotecan central nervous system penetration is altered by a tyrosine kinase inhibitor. Cancer Res. 2006;66(23): 11305-11313.
29. Heideman RL, Cole DE, Balis F, et al. Phase I and pharmacokinetic evaluation of thiotepa in the cerebrospinal fluid and plasma of pediatric patients: evidence for dose-dependent plasma clearance of thiotepa. Cancer Res. 1989;49(3): 736-741.
30. Vassal G, Gouyette A, Hartmann O, Pico JL, Lemerle J. Pharmacokinetics of high-dose busulfan in children. Cancer Chemother Pharmacol. 1989;24(6): 386-390.
31. Ostermann S, Csajka C, Buclin T, et al. Plasma and cerebrospinal fluid population pharmacokinetics of temozolomide in malignant glioma patients. Clin Cancer Res. 2004;10(11):3728-3736.
32. Patel M, McCully C, Godwin K, Balis FM. Plasma and cerebrospinal fluid pharmacokinetics of intravenous temozolomide in non-human primates. J Neurooncol. 2003;61(3):203-207.
33. Berg SL, Gerson SL, Godwin K, Cole DE, Liu L, Balis FM. Plasma and cerebrospinal fluid pharmacokinetics of O6-benzylguanine and time course of peripheral blood mononuclear cell O6-methylguanine-DNA methyltransferase inhibition in the nonhuman primate. Cancer Res. 1995;55(20):4606-4610.
34. Grygiel JJ, Balis FM, Collins JM, Lester CM, Poplack DG. Pharmacokinetics of tiazofurin in the plasma and cerebrospinal fluid of rhesus monkeys. Cancer Res. 1985;45(5):2037-2039.
35. Zimm S, Ettinger LJ, Holcenberg JS, et al. Phase I and clinical pharmacological study of mercaptopurine administered as a prolonged intravenous infusion. Cancer Res. 1985;45(4):1869-1873.
36. Kerr IG, Zimm S, Collins JM, O'Neill D, Poplack DG. Effect of intravenous dose and schedule on cerebrospinal fluid pharmacokinetics of 5-fluorouracil in the monkey. Cancer Res. 1984;44(11):4929-4932.
37. Heideman RL, Balis FM, McCully C, Poplack DG. Preclinical pharmacology of arabinosyl-5-azacytidine in nonhuman primates. Cancer Res. 1988;48(15): 4294-4298.
38. Balis FM, Poplack DG. Central nervous system pharmacology of antileukemic drugs. Am J Pediatr Hematol Oncol. 1989;11(1):74-86.
39. Slevin ML, Piall EM, Aherne GW, Harvey VJ, Johnston A, Lister TA. Effect of dose and schedule on pharmacokinetics of high-dose cytosine arabinoside in plasma and cerebrospinal fluid. J Clin Oncol. 1983;1(9):546-551.
40. Kerr JZ, Berg SL, Dauser R, et al. Plasma and cerebrospinal fluid pharmacokinetics of gemcitabine after intravenous administration in nonhuman primates. Cancer Chemother Pharmacol. 2001;47(5):411-414.
41. Berg SL, Bonate PL, Nuchtern JG, et al. Plasma and cerebrospinal fluid pharmacokinetics of clofarabine in nonhuman primates. Clin Cancer Res. 2005; 11(16):5981-5983.
42. Kellie SJ, Barbaric D, Koopmans P, Earl J, Carr DJ, de Graaf SS. Cerebrospinal fluid concentrations of vincristine after bolus intravenous dosing: a surrogate marker of brain penetration. Cancer. 2002;94(6):1815-1820.
43. Heideman RL, Kelley JA, Packer RJ, et al. A pediatric phase I and pharmacokinetic study of spirohydantoin mustard. Cancer Res. 1988;48(8):2292-2295.
44. DeGregorio MW, King OY, Holleran WM, et al. Ultrafiltrate and total platinum in plasma and cerebrospinal fluid in a patient with neuroblastoma. Cancer Treat Rep. 1985;69(12):1441-1442.
45. Jacobs SS, Fox E, Dennie C, Morgan LB, McCully CL, Balis FM. Plasma and cerebrospinal fluid pharmacokinetics of intravenous oxaliplatin, cisplatin, and carboplatin in nonhuman primates. Clin Cancer Res. 2005;11(4):1669-1674.
46. Hande KR, Wedlund PJ, Noone RM, Wilkinson GR, Greco FA, Wolff SN. Pharmacokinetics of high-dose etoposide (VP-16-213) administered to cancer patients. Cancer Res. 1984;44(1):379-382.
47. Relling MV, Mahmoud HH, Pui CH, et al. Etoposide achieves potentially cytotoxic concentrations in CSF of children with acute lymphoblastic leukemia. J Clin Oncol. 1996;14(2):399-404.
48. Thyss A, Milano G, Deville A, Manassero J, Renee N, Schneider M. Effect of dose and repeat intravenous 24 hr infusions of methotrexate on cerebrospinal fluid availability in children with hematological malignancies. Eur J Cancer Clin Oncol. 1987;23(6):843-847.
49. Balis FM, Blaney SM, McCully CL, Bacher JD, Murphy RF, Poplack DG. Methotrexate distribution within the subarachnoid space after intraventricular and intravenous administration. Cancer Chemother Pharmacol. 2000;45(3):259-264.
50. Stapleton SL, Reid JM, Thompson PA, et al. Plasma and cerebrospinal fluid pharmacokinetics of pemetrexed after intravenous administration in non-human primates. Cancer Chemother Pharmacol. 2007;59(4):461-466.
51. Habif DV, Lipton R, Cantell K. Interferon crosses blood-cerebrospinal fluid barrier in monkeys. Proc Soc Exp Biol Med. 1975;149(1):287-289.
52. Pestalozzi BC, Brignoli S. Trastuzumab in CSF. J Clin Oncol. 2000;18(11):2349-2351.
53. Stemmler J, Schmitt M, Willems A, Bernhard H, Harbeck N, Heinemann V. Brain metastases in HER2-overexpressing metastatic breast cancer: comparative analysis of trastuzumab levels in serum and cerebrospinal fluid [abstract]. J Clin Oncol 2006 ASCO Annual Meeting Proceedings. 2006;24(18S)(suppl):1525.
54. Berg SL, Reid J, Godwin K, et al. Pharmacokinetics and cerebrospinal fluid penetration of daunorubicin, idarubicin, and their metabolites in the nonhuman primate model. J Pediatr Hematol Oncol. 1999;21(1):26-30.
55. Baker SD, Heideman RL, Crom WR, Kuttesch JF, Gajjar A, Stewart CF. Cerebrospinal fluid pharmacokinetics and penetration of continuous infusion topotecan in children with central nervous system tumors. Cancer Chemother Pharmacol. 1996;37(3):195-202.
56. Blaney SM, Takimoto C, Murry DJ, et al. Plasma and cerebrospinal fluid pharmacokinetics of 9-aminocamptothecin (9-AC), irinotecan (CPT-11), and SN-38 in nonhuman primates. Cancer Chemother Pharmacol. 1998;41(6):464-468.
57. Rubenstein JL, Combs D, Rosenberg J, et al. Rituximab therapy for CNS lymphomas: targeting the leptomeningeal compartment. Blood. 2003;101(2): 466-468.
58. Rubenstein JL, Rosenberg J, Damon L. High-dose methotrexate plus rituximab (anti-CD20) monoclonal antibody in the treatment of primary CNS lymphoma. Paper presented at: Society for Neuro-Oncology Fourth Annual Meeting; November 19, 1999; Scottsdale, AZ.
59. Meany HJ, Fox E, McCully C, Tucker C, Balis FM. The plasma and cerebrospinal fluid pharmacokinetics of erlotinib and its active metabolite (OSI-420) after intravenous administration of erlotinib in non-human primates. Cancer Chemother Pharmacol. 2008;62(3):387-392.
60. Neville K, Parise RA, Thompson P, et al. Plasma and cerebrospinal fluid pharmacokinetics of imatinib after administration to nonhuman primates. Clin Cancer Res. 2004;10(7):2525-2529.
61. Berg SL, Stone J, Xiao JJ, et al. Plasma and cerebrospinal fluid pharmacokinetics of depsipeptide (FR901228) in nonhuman primates. Cancer Chemother Pharmacol. 2004;54(1):85-88.
62. Stapleton SL, Thompson PA, Ou CN, et al. Plasma and cerebrospinal fluid pharmacokinetics of valproic acid after oral administration in non-human primates. Cancer Chemother Pharmacol. 2008;61(4):647-652.
63. Beckloff GL, Lerner HJ, Frost D, Russo-Alesi FM, Gitomer S. Hydroxyurea (NSC-32065) in biologic fluids: dose-concentration relationship. Cancer Chemother Rep. 1965;48:57-58.
64. Muscal JA, Thompson PA, Giranda VL, et al. Plasma and cerebrospinal fluid pharmacokinetics of ABT-888 after oral administration in non-human primates. Cancer Chemother Pharmacol. 2010;65(3):419-425.
65. Kilburn LB, Bonate PL, Blaney SM, et al. Plasma and cerebrospinal fluid pharmacokinetics of tasidotin (ILX-651) and its metabolites in non-human primates. Cancer Chemother Pharmacol. 2009;64(2):335-340.
66. Yule SM, Price L, Pearson AD, Boddy AV. Cyclophosphamide and ifosfamide metabolites in the cerebrospinal fluid of children. Clin Cancer Res. 1997; 3(11):1985-1992.
67. Levin VA, Groves MD, Forman AD. Intraventricular and intrathecal therapy. In: Perry MC, ed. The Chemotherapy Sourcebook. 4th ed. Philadelphia, PA: Lippincott Williams and Wilkins; 2008:65-74.
68. Stemmler HJ, Schmitt M, Willems A, Bernhard H, Harbeck N, Heinemann V. Ratio of trastuzumab levels in serum and cerebrospinal fluid is altered in HER2-positive breast cancer patients with brain metastases and impairment of bloodbrain barrier. Anticancer Drugs. 2007;18(1):23-28.
69. Rogers LR, Chamberlain M, Glantz M. Evidence-based review of intrathecal chemotherapy in outcome of patients with leptomeningeal metastasis [abstract]. J Clin Oncol 2006 ASCO Annual Meeting Proceedings. 2006;24(18S)(suppl): 1529.
70. Glantz MJ, LaFollette S, Jaeckle KA, et al. Randomized trial of a slow-release versus a standard formulation of cytarabine for the intrathecal treatment of lymphomatous meningitis. J Clin Oncol. 1999;17(10):3110- 3116.
71. Glantz MJ, Jaeckle KA, Chamberlain MC, et al. A randomized controlled trial comparing intrathecal sustained-release cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors. Clin Cancer Res. 1999;5(11):3394-3402.
72. Rudnicka H, Niwinska A, Murawska M. Breast cancer leptomeningeal metastasis-the role of multimodality treatment. J Neurooncol. 2007;84(1):57-62.
73. Boogerd W, van den Bent MJ, Koehler PJ, et al. The relevance of intraventricular chemotherapy for leptomeningeal metastasis in breast cancer: a randomised study. Eur J Cancer. 2004;40(18):2726-2733.
74. Siegal T. Leptomeningeal metastases: rationale for systemic chemotherapy or what is the role of intra-CSF-chemotherapy? J Neurooncol. 1998;38(2-3):151-157.
75. Fleischhack G, Jaehde U, Bode U. Pharmacokinetics following intraventricular administration of chemotherapy in patients with neoplastic meningitis. Clin Pharmacokinet. 2005;44(1):1-31.
76. Glantz MJ, Chamberlain MC, Batchelor T, Wong E, Cavalli F, Shapiro WR. Interaction between route of intra-CSF chemotherapy administration and efficacy of therapy in patients with neoplastic meningitis [abstract]. J Clin Oncol 2006 ASCO Annual Meeting Proceedings. 2006;24(18S)(suppl):1530.
77. Chamberlain MC, Tsao-Wei DD, Groshen S. Phase II trial of intracerebrospinal fluid etoposide in the treatment of neoplastic meningitis. Cancer. 2006;106 (9):2021-2027.
78. Groves MD, Glantz MJ, Chamberlain MC, et al. A multicenter phase II trial of intrathecal topotecan in patients with meningeal malignancies. Neuro Oncol. 2008;10(2):208-215.
79. Blaney SM, Balis FM, Berg S, et al. Intrathecal mafosfamide: a preclinical pharmacology and phase I trial. J Clin Oncol. 2005;23(7):1555-1563.
80. Blaney SM, Boyett J, Friedman H, et al. Phase I clinical trial of mafosfamide in infants and children aged 3 years or younger with newly diagnosed embryonal tumors: a pediatric brain tumor consortium study (PBTC-001). J Clin Oncol. 2005;23(3):525-531.
81. Gururangan S, Petros WP, Poussaint TY, et al. Phase I trial of intrathecal spartaject busulfan in children with neoplastic meningitis: a Pediatric Brain Tumor Consortium Study (PBTC-004). Clin Cancer Res. 2006;12(5):1540-1546.
82. Quinn JA, Glantz M, Petros W, et al. Intrathecal spartaject busulfan phase I trial for patients with neoplastic meningitis [abstract]. Neuro-oncol. 2001;3(4):364.
83. Nakagawa H, Miyahara E, Suzuki T, Wada K, Tamura M, Fukushima Y. Continuous intrathecal administration of 5-fluoro-2'-deoxyuridine for the treatment of neoplastic meningitis. Neurosurgery. 2005;57(2):266-280.
84. Wong FC, Groves M, Papadopoulos N, et al. Toxicity and efficacy profiles of intrathecal injection of I-131 NaI via intraventricular (IVent) or intralumbar (Ilumb) route for leptomeningeal metastases (LM) therapy [abstract]. J Clin Oncol 2006 ASCO Annual Meeting Proceedings. 2006;24(18S)(suppl): 1549.
85. Kramer K, Humm JL, Souweidane MM, et al. Phase I study of targeted radio-immunotherapy for leptomeningeal cancers using intra-Ommaya 131-I-3F8. J Clin Oncol. 2007;25(34):5465-5470.
86. Groves MD. Leptomeningeal Metastases: Still a Challenge. Alexandria, VA: American Society of Clinical Oncology; 2008:80-87.
87. Blaney SM, Heideman R, Berg S, et al. Phase I clinical trial of intrathecal topotecan in patients with neoplastic meningitis. J Clin Oncol. 2003;21(1):143-147.
88. Herrlinger U, Weller M, Schabet M. New aspects of immunotherapy of leptomeningeal metastasis. J Neurooncol. 1998;38(2-3):233-239.
89. Chamberlain MC. A phase II trial of intra-cerebrospinal fluid alpha interferon in the treatment of neoplastic meningitis. Cancer. 2002;94(10):2675-2680.
90. Rubenstein JL, Fridlyand J, Abrey L, et al. Phase I study of intraventricular administration of rituximab in patients with recurrent CNS and intraocular lymphoma. J Clin Oncol. 2007;25(11):1350-1356.
91. Chamberlain MC, Glantz MJ. Intra-CSF rituximab for lymhomatous meningitis. J Clin Oncol. 2007;25(28):4508-4509.
92. Allison DL, Glantz M, Werner TL, Kirkegaard SL, Murdock K, Jensen RL. Intra-CSF trastuzumab in patients with neoplastic meningitis from breast cancer or primary brain tumors [abstract]. J Clin Oncol 2009 ASCO Annual Meeting Proceedings. 2009;27(15S)(suppl):2006.
93. Herrlinger U, Forschler H, Kuker W, et al. Leptomeningeal metastasis: survival and prognostic factors in 155 patients. J Neurol Sci. 2004;223(2):167-178.
94. Siegal T, Lossos A, Pfeffer MR. Leptomeningeal metastases: analysis of 31 patients with sustained off-therapy response following combined-modality therapy. Neurology. 1994;44(8):1463-1469.
95. Grant R, Naylor B, Greenberg HS, Junck L. Clinical outcome in aggressively treated meningeal carcinomatosis. Arch Neurol. 1994;51(5):457-461.
96. de Wit M, Lange-Brock V, Kruell A, Bokemeter C. Leptomeningeal metastases: results of different therapeutic approaches [abstract]. J Clin Oncol 2007 ASCO Annual Meeting Proceedings. 2007;25(18S)(suppl):2047.
97. Fizazi K, Asselain B, Vincent-Salomon A, et al. Meningeal carcinomatosis in patients with breast carcinoma: clinical features, prognostic factors, and results of a high-dose intrathecal methotrexate regimen. Cancer. 1996;77(7):1315-1323.
98. Mencel PJ, DeAngelis LM, Motzer RJ. Hormonal ablation as effective therapy for carcinomatous meningitis from prostatic carcinoma. Cancer. 1994;73 (7):1892-1894.
99. Boogerd W, Dorresteijn LD, van Der Sande JJ, de Gast GC, Bruning PF. Response of leptomeningeal metastases from breast cancer to hormonal therapy. Neurology. 2000;55(1):117-119.
100. Ozdogan M, Samur M, Bozcuk HS, et al. Durable remission of leptomeningeal metastasis of breast cancer with letrozole: a case report and implications of biomarkers on treatment selection. Jpn J Clin Oncol. 2003;33(5):229-231.
101. Boogerd W, Hart AA, van der Sande JJ, Engelsman E. Meningeal carcinomatosis in breast cancer: prognostic factors and influence of treatment. Cancer. 1991;67(6):1685-1695.
102. Glantz MJ, Cole BF, Recht L, et al. High-dose intravenous methotrexate for patients with nonleukemic leptomeningeal cancer: is intrathecal chemotherapy necessary? J Clin Oncol. 1998;16(4):1561-1567.
103. Giglio P, Tremont-Lukats IW, Groves MD. Response of neoplastic meningitis from solid tumors to oral capecitabine. J Neurooncol. 2003;65(2):167-172.
104. Ekenel M, Hormigo AM, Peak S, DeAngelis LM, Abrey LE. Capecitabine therapy of central nervous system metastases from breast cancer. J Neurooncol. 2007; 85(2):223-227.
105. Tham YL, Hinckley L, Teh BS, Elledge R. Long-term clinical response in leptomeningeal metastases from breast cancer treated with capecitabine monotherapy: a case report. Clin Breast Cancer. 2006;7(2):164-166.
106. Davis TH, Fadul CE, Glantz MJ, et al. Pilot phase II trial of temozolomide for leptomeningeal metastases: preliminary report [abstract]. J Clin Oncol 2003 ASCO Annual Meeting Proceedings. 2003;22(115a)(suppl):460.
107. Groves MD, Hess KR, Puduvalli VK, et al. Biomarkers of disease: cerebrospinal fluid vascular endothelial growth factor (VEGF) and stromal cell derived factor (SDF)-1 levels in patients with neoplastic meningitis (NM) due to breast cancer, lung cancer and melanoma. J Neurooncol. 2009;94(2):229-234.
108. Stockhammer G, Poewe WF, Burgstaller SF, et al. Vascular endothelial growth factor in CSF: a biological marker for carcinomatous meningitis. Neurology. 2000; 54(8):1670-1676.
109. Herrlinger U, Wiendl H, Renninger M, Forschler H, Dichgans J, Weller M. Vascular endothelial growth factor (VEGF) in leptomeningeal metastasis: diagnostic and prognostic value. Br J Cancer. 2004;91(2):219-224.
110. Choong NW, Dietrich S, Seiwert TY, et al. Gefitinib response of erlotinibrefractory lung cancer involving meninges - role of EGFR mutation. Nat Clin Pract Oncol. 2006;3(1):50-57.
111. Kanaji N, Bandoh S, Nagamura N, Kushida Y, Haba R, Ishida T. Significance of an epidermal growth factor receptor mutation in cerebrospinal fluid for carcinomatous meningitis. Intern Med. 2007;46(19):1651-1655.
112. High dose gefitinib for the treatment of carcinomatous meningitis in adult patients with non-small cell lung cancer and known or suspected EGFR mutations. Clinicaltrials.gov Web site. http://clinicaltrials.gov/ct2/show/ NCT00372515. Accessed July 1, 2009.
113. Hill FG, Richards S, Gibson B, et al; UK Medical Research Council Working Party on Childhood Leukaemia. Successful treatment without cranial radiotherapy of children receiving intensified chemotherapy for acute lymphoblastic leukaemia: results of the risk-stratified randomized central nervous system treatment trial MRC UKALL XI (ISRC TN 16757172). Br J Haematol. 2004;124(1):33-46.
114. Hill QA, Owen RG. CNS prophylaxis in lymphoma: who to target and what therapy to use. Blood Rev. 2006;20(6):319-332.
115. Norris LKF, Grossman SAF, Olivi A. Neoplastic meningitis following surgical resection of isolated cerebellar metastasis: a potentially preventable complication. J Neurooncol. 1997;32(3):215-223.
116. Siomin VE, Vogelbaum MA, Kanner AA, Lee SY, Suh JH, Barnett GH. Posterior fossa metastases: risk of leptomeningeal disease when treated with stereotactic radiosurgery compared to surgery. J Neurooncol. 2004;67(1-2):115-121.
117. van der Ree TC, Dippel DW, Avezaat CJ, Sillevis Smitt PA, Vecht CJ, van den Bent MJ. Leptomeningeal metastasis after surgical resection of brain metastases. J Neurol Neurosurg Psychiatry. 1999;66(2):225-227.
118. Suki D, Abouassi H, Patel AJ, Sawaya R, Weinberg JS, Groves MD. Comparative risk of leptomeningeal disease after resection or stereotactic radiosurgery for solid tumor metastasis to the posterior fossa. J Neurosurg. 2008;108 (2):248-257.
119. Suki D, Hatiboglu MA, Patel AJ, et al. Comparative risk of leptomeningeal dissemination of cancer after surgery or stereotactic radiosurgery for a single supratentorial solid tumor metastasis. Neurosurgery. 2009;64(4):664-674.